PD-1/PD-L1抑制剂治疗晚期肝细胞癌的研究进展  

Research progress of PD-1/PD-L1 inhibitors in treating advanced hepatocellular carcinoma

作　　者：刘红燕 杨平[1,2] LIU Hong-yan;YANG Ping(Affiliated Naval Clinical College of Anhui Medical University,Hefei ANHUI 230032,China;Department of Oncology,the Sixth Medical Center of PIA General Hospital,BEIJING 100048,China)

机构地区：[1]安徽医科大学海军临床学院,安徽合肥230032 [2]中国人民解放军总医院第六医学中心肿瘤科,北京100048

出　　处：《中国新药与临床杂志》2021年第2期81-86,共6页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：随着肿瘤免疫治疗的不断应用,免疫检查点抑制剂(ICI)治疗肿瘤的相关临床研究开展广泛。多项研究表明,以程序性死亡受体/配体1(PD-1/PD-L1)抑制剂为代表的ICI在肝细胞癌治疗中取得了较好的疗效并改善了患者生存期;除单药治疗外,PD-1/PD-L1抑制剂还能与化疗、靶向药物及其他ICI联合治疗。但免疫治疗相关不良事件限制了PD-1/PD-L1抑制剂的临床广泛应用,且还需进一步明确生物标志物以用于评估疗效。With the continuous application of tumor immunotherapy, clinical studies on immune checkpoint inhibitors(ICI) in the treatment of tumor have been widely carried out. A number of studies have shown that ICI, represented by programmed death receptor/ligand 1(PD-1/PD-L1) inhibitors, has achieved good efficacy in the treatment of hepatocellular carcinoma and improved patient survival. In addition to single-drug therapy, it can also be combined with chemotherapy, targeted drugs and other ICI therapy. However, immunotherapy-related adverse events limited the clinical application of PD-1/PD-L1 inhibitors, and the biological markers need to be defined to evaluate the efficacy.

关 键 词：癌 肝细胞 程序性死亡受体/配体抑制剂 临床研究 肿瘤免疫治疗 

分 类 号：R392.1[医药卫生—免疫学] R730.261[医药卫生—基础医学]